GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » Short Interest

WuXi Biologics (Cayman) (FRA:1FW2) Short Interest


View and export this data going back to 2017. Start your Free Trial

What is WuXi Biologics (Cayman) Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of WuXi Biologics (Cayman)'s Short Interest

For the Biotechnology subindustry, WuXi Biologics (Cayman)'s Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

WuXi Biologics (Cayman)'s Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, WuXi Biologics (Cayman)'s Short Interest distribution charts can be found below:

* The bar in red indicates where WuXi Biologics (Cayman)'s Short Interest falls into.


WuXi Biologics (Cayman) (FRA:1FW2) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (FRA:1FW2) » Definitions » Short Interest
Comparable Companies
HKSE:01801 HKSE:01177 HKSE:01548 HKSE:01877 HKSE:09926 HKSE:09995 HKSE:06990 HKSE:01530 HKSE:06826 HKSE:02162 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX BNTX BGNE
Traded in Other Exchanges
WXIBF:USA WXXWY:USA 2269:Mexico 02269:Hong Kong 1FW1:Germany
Address
No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092
Website
https://www.wuxibiologics.com
WuXi Biologics is one of the largest global biologics CRDMOs. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 15 billion. North American represented 55.6% of total revenue in 2022. It adopts the follow and win the molecule strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual-sourcing strategy by providing drug products and large-scale drug substance manufacturing.

WuXi Biologics (Cayman) (FRA:1FW2) Headlines

No Headlines